<main class="html-publication" lang="en" role="main">
      

  <div class="publication-external">
    <ul class="organisation-logos">
        <li class="organisation-logos__logo">
          
<div class="gem-c-organisation-logo brand--department-of-health">
    <a class="gem-c-organisation-logo__container gem-c-organisation-logo__link gem-c-organisation-logo__crest gem-c-organisation-logo__crest--single-identity brand__border-color" href="/government/organisations/uk-health-security-agency">
      <span class="gem-c-organisation-logo__name">UK Health<br>Security<br>Agency</span>
</a>
</div>
        </li>
    </ul>
  </div>

  <header class="gem-c-inverse-header  gem-c-inverse-header--padding-top ">
    
  

<div class="gem-c-title gem-c-title--inverse govuk-!-margin-top-8 govuk-!-margin-bottom-0">
      <span class="govuk-caption-xl gem-c-title__context">
    Guidance
  </span>


  <h1 class="gem-c-title__text govuk-heading-xl">
    SARS-CoV-2 variant of concern diagnostic assurance
  </h1>
</div>
  <p class="publication-header__last-changed">Updated 14 April 2022</p>

  </header>



<div class="govuk-grid-row sidebar-with-body" data-module="sticky-element-container">

  <div class="print-wrapper">
    <div class="print-meta-data">
      <p>
  <img class="print-meta-data-licence" src="/assets/government-frontend/open-government-licence-min-93b6a51b518ff99714a1aa2a7d2162735c155ec3cb073c75fb88b2a332fa83d3.png">
</p>
<p>
  Â© Crown copyright 2022
</p>
<p>
  This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit <a href="https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3">nationalarchives.gov.uk/doc/open-government-licence/version/3</a> or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: <a href="mailto:psi@nationalarchives.gov.uk">psi@nationalarchives.gov.uk</a>.
</p>
<p>
  Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
</p>
<p>
  This publication is available at https://www.gov.uk/government/publications/sars-cov-2-variant-of-concern-diagnostic-assurance/sars-cov-2-variant-of-concern-diagnostic-assurance
</p>


    </div>
  </div>

  <div class="main-content-container offset-empty-contents-list">
    <div class="gem-c-govspeak-html-publication">
  
<div class="gem-c-govspeak govuk-govspeak " data-module="govspeak">
    
    
      <div class="govspeak">
<p>The UK Health Security Agency (<abbr title="UK Health Security Agency">UKHSA</abbr>) NHS Test and Trace programme carefully monitors test performance to provide assurance that nucleic acid and antigen tests that are in use by public providers are able to detect new SARS-CoV-2 variants (variants of concern (<abbr title="variants of concern">VOCs</abbr>) and emerging variants (<abbr title="variant">V</abbr>)).</p>

<p><a class="govuk-link" href="https://www.gov.uk/government/collections/new-sars-cov-2-variant">Find out more about COVID-19 (SARS-CoV-2) variants</a></p>

<p>Assurance processes, guidance and standards have been developed by members of the Variants of Concern Assurance Group. Members of the group include expert scientists and clinicians from all 4 UK administrations and representatives from the Medicines and Healthcare products Regulatory Agency (<abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr>).</p>

<p>The <abbr title="variant of concern">VOC</abbr> Assurance Group and <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> monitor the performance of assays through:</p>

<ul>
  <li>in silico monitoring (based on computer modelling)</li>
  <li>laboratory test performance quality monitoring</li>
  <li>in vitro testing (where indicated by the in silico and quality monitoring processes)</li>
</ul>

<p><abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> regularly engages with suppliers and manufacturers of test products in the UK to review their post-market assurance processes for the most recently published <abbr title="variants of concern">VOCs</abbr> and <abbr title="variants">Vs</abbr> in circulation in the UK.</p>

<p>When a test product is impacted by a <abbr title="variant of concern">VOC</abbr> or <abbr title="variant">V</abbr>, <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> works with manufacturers to take mitigative actions and inform testing service providers.</p>

<p>All testing service providers (both public and private) can independently raise performance concerns using the dedicated <a class="govuk-link" href="https://coronavirus-yellowcard.mhra.gov.uk" rel="external">coronavirus Yellow Card reporting system</a>.</p>

<p>Urgent enquiries related to <abbr title="variants of concern">VOCs</abbr> should be reported to <a class="govuk-link" href="mailto:covid19.variants@mhra.gov.uk">covid19.variants@mhra.gov.uk</a></p>

<p>Private providers of SARS-CoV-2 antigen and nucleic acid tests should contact the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> at <a class="govuk-link" href="mailto:device.registrations@mhra.gov.uk">device.registrations@mhra.gov.uk</a> to confirm that their tests products are registered and monitored.</p>

</div>


</div>
</div>
  </div>

  <div class="sticky-element" data-sticky-element="">
    <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" focusable="false" height="17" viewBox="0 0 13 17" width="13" xmlns="http://www.w3.org/2000/svg">
      <path d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z" fill="currentColor"></path>
    </svg>
    Contents
</a>

    <div class="sticky-element__print-link">
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link govuk-body-s gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>
    </div>
  </div>
</div>

    </main>